Bladder Cancer Coverage from Every Angle

Nicholas Vogelzang, MD, on Urothelial Cancer: Lenvatinib Plus Pembrolizumab

Posted: Tuesday, March 5, 2019

Nicholas Vogelzang, MD, of the Comprehensive Cancer Centers of Nevada, discusses how the combination of lenvatinib and pembrolizumab may fit into the future treatment landscape for patients with urothelial cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.